Neoprobe Corporation (NEOP) is an innovator in gamma-guided surgery, dedicated to developing and commercializing new biomedical products to improve the diagnosis, treatment, and quality of life of cancer patients. The company’s subsidiary, Cira Biosciences, Inc., explores the development and commercialization of an activated cellular therapy technology that has shown promising early stage, patient-specific treatment potential in oncology, and viral (HIV/AIDS and hepatitis) and autoimmune diseases. The company’s products are available throughout the world from major distributors, and are supported by a worldwide servicing capability.
Neoprobe Corporation markets their neo2000® Gamma Detection Systems, which include detector probes and accessories, worldwide for surgical procedures called intra-operative lymphatic mapping (ILM) of the sentinel node – a minimally invasive technique for evaluating the potential spread of cancer to lymph node tissues and organs. Currently, multiple large-scale national and international studies are underway to further evaluate the survival advantage of ILM staging in patients with melanoma and breast cancer. Surgeons are using lymphatic mapping to help trace lymphatic patterns in a cancer patient to evaluate potential tumor drainage and cancer spread in lymphatic tissue.
Through their wholly owned subsidiary, Cardiosonix Ltd., Neoprobe has developed the Quantix line of blood flow measurement products to be used for a variety of clinical needs, including: real-time monitoring, intra-operative quantification, non-invasive diagnostics, and the evaluation of blood flow. The blood flow measurement products employ patented Doppler blood flow measurement technology and algorithms, which allows for real-time, angle-independent blood flow volume and velocity readings. Utilizing the Doppler blood flow, the angle of incision can be obtained without the need to use complicated imaging systems, allowing for a more precise measurement of the volume of total blood flow.
Let us hear your thoughts: Neoprobe Corp. Message Board
